PuSH - Publikationsserver des Helmholtz Zentrums München: Mutant <em>KRAS </em>promotes malignant pleural effusion formation.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Αgalioti, T.* ; Giannou, A.D.* ; Krontira, A.C.* ; Kanellakis, N.I.* ; Kati, D.* ; Vreka, M. ; Pepe, M. ; Spella, M.* ; Lilis, I.* ; Zazara, D.E.* ; Nikolouli, E.* ; Spiropoulou, N.* ; Papadakis, A.* ; Papadia, K.* ; Voulgaridis, A.* ; Harokopos, V.* ; Stamou, P.* ; Meiners, S. ; Eickelberg, O. ; Snyder, L.A.* ; Antimisiaris, S.G.* ; Kardamakis, D.* ; Psallidas, I.* ; Μarazioti, A.* ; Stathopoulos, G.T.

Mutant KRAS promotes malignant pleural effusion formation.

Nat. Commun. 8:15205 (2017)

Verlagsversion

Forschungsdaten

DOI

PMC

	Open Access Gold

Abstract
Metriken
Zusatzinfos

Malignant pleural effusion (MPE) is the lethal consequence of various human cancers metastatic to the pleural cavity. However, the mechanisms responsible for the development of MPE are still obscure. Here we show that mutant KRAS is important for MPE induction in mice. Pleural disseminated, mutant KRAS bearing tumour cells upregulate and systemically release chemokine ligand 2 (CCL2) into the bloodstream to mobilize myeloid cells from the host bone marrow to the pleural space via the spleen. These cells promote MPE formation, as indicated by splenectomy and splenocyte restoration experiments. In addition, KRAS mutations are frequently detected in human MPE and cell lines isolated thereof, but are often lost during automated analyses, as indicated by manual versus automated examination of Sanger sequencing traces. Finally, the novel KRAS inhibitor deltarasin and a monoclonal antibody directed against CCL2 are equally effective against an experimental mouse model of MPE, a result that holds promise for future efficient therapies against the human condition.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

12.124

2.995